Other serum markers, such as osteopontin, Golgi protein-73 or glypican-3 may offer information about the biological aggressiveness of HCC, but they are not erratic and accurate enough to form part of a screening strategy (7–9). This evidence concerns the gene GPC3 and hepatocellular carcinoma.